# Thymulin Dosage in the Research Literature

> thymulin dosage as used in preclinical models: concentrations, routes, and study durations indexed from the peer-reviewed literature. No validated human dosing protocol exists.

## Thymulin Dosage in the Research Literature

thymulin dosage in peer-reviewed studies spans a wide range across species and experimental contexts — from picomolar concentrations in pituitary cell culture to milligram-per-kilogram doses in nanoparticle formulations. No validated human pharmacokinetic data exist for subcutaneous, intramuscular, or any other common administration route.

## Thymulin Dosage in Preclinical Models

**Rodent pain and inflammation models (PAT analogue)**
Safieh-Garabedian et al. (2002) used 1–200 μg/rat intraperitoneally and 25 μg intraplantar in adult male Sprague-Dawley rats [6]. At 25 μg, pain thresholds returned to control levels. In the neuropathic pain models (Saade et al. 2003), 0.25–50 μg/rat intraperitoneally produced peak inhibition 1–2 hours post-treatment [7].

**Rodent neuroinflammation models (thymulin)**
Safieh-Garabedian et al. (2003) administered 0.1, 0.5, and 1 μg in 5 μL saline intracerebroventricularly in male Sprague-Dawley rats [8].

**Mouse cytokine and inflammation models**
Lunin et al. (2008) used 15 μg/100g body weight intraperitoneally in male NMRI mice [9].

**Murine EAE (nanoparticle formulation)**
Lunin et al. (2019) used 1.5 mg/kg thymulin equivalent (PBCA nanoparticle-encapsulated) intraperitoneally every other day for 25 days in female SJL/J mice [13].

**Avian NK cell studies**
Oliver and Marsh (2003) used 10 ng/100g and 50 ng/100g body weight daily in K-strain chickens [10].

**In vitro pituitary cells**
Hadley et al. (1997) used 0.5–50 pM Zn-thymulin; maximal ACTH stimulation occurred at 10 pM [11].

## Half-Life and Stability

No definitive pharmacokinetic study characterizing thymulin's half-life in human plasma exists in the peer-reviewed literature. Stability requires zinc at physiological pH (7.4); activity drops to zero below pH 6.0 [1]. The short plasma half-life problem motivated PBCA nanoparticle encapsulation [13] and adenoviral gene therapy [12] approaches.

## Administration Route in Research Protocols

- **Intraperitoneal** — most common rodent route [6, 7, 9, 13]
- **Intravenous** — boar reproductive studies (Wise & Ford 1999) [14]
- **Intracerebroventricular** — neuroinflammation models [8, 15]
- **Intramuscular** — gene therapy vector delivery (Reggiani 2006) [12]
- **Topical spray** — zinc-thymulin scalp application (Vickers 2017) [17]

## Thymulin Safety Profile in Preclinical Studies

Preclinical models report minimal adverse effects at studied concentrations [9, 13, 17]. No IND or NDA for the synthetic thymulin nonapeptide has been identified with the FDA. The bidirectional dose-response (low-dose NK enhancement vs. high-dose NK suppression [10]) is a notable preclinical safety signal.

## References

[1] Dardenne M, Pleau JM. Interactions Between Zinc and Thymulin. Metal-Based Drugs. 1994;1(4):233-249. DOI: 10.1155/MBD.1994.233
[4] Prasad AS, et al. Serum thymulin in human zinc deficiency. J Clin Invest. 1988;82(4):1202-10. DOI: 10.1172/JCI113717
[5] Mocchegiani E, Fabris N. Age-related thymus involution: zinc reverses the thymulin secretion defect. Int J Immunopharmacol. 1995;17(9):745-9. DOI: 10.1016/0192-0561(95)00064-9
[6] Safieh-Garabedian B, et al. Potent analgesic and anti-inflammatory actions of a novel thymulin-related peptide. Br J Pharmacol. 2002;136(7):947-55. DOI: 10.1038/sj.bjp.0704793
[7] Saade NE, et al. A thymulin analogue peptide with powerful inhibitory effects on pain. Neuroscience. 2003;119(2):529-40. DOI: 10.1016/s0306-4522(03)00072-1
[8] Safieh-Garabedian B, et al. Thymulin reverses inflammatory hyperalgesia. Neuroscience. 2003;122(4):1049-61. DOI: 10.1016/s0306-4522(03)00500-1
[9] Lunin SM, et al. Thymulin prevents the overproduction of pro-inflammatory cytokines. Immunol Invest. 2008;37(8):858-71. DOI: 10.1080/08820130802447629
[10] Oliver MA, Marsh JA. In vivo thymulin treatments enhance avian NK cell cytotoxicity. Int Immunopharmacol. 2003;3(3):271-80. DOI: 10.1016/s1567-5769(02)00236-9
[11] Hadley AJ, et al. Thymulin stimulates corticotrophin release. Neuroimmunomodulation. 1997;4(2):62-9. DOI: 10.1159/000097322
[12] Reggiani PC, et al. Gene therapy for long-term restoration of circulating thymulin. Gene Ther. 2006;13(16):1214-21. DOI: 10.1038/sj.gt.3302775
[13] Lunin SM, et al. Protective Effect of PBCA Nanoparticles Loaded with Thymulin Against Relapsing-Remitting EAE. Int J Mol Sci. 2019;20(21):5374. DOI: 10.3390/ijms20215374
[14] Wise T, Ford JJ. Effects of the thymic peptide thymulin on testicular steroid concentrations. J Anim Sci. 1999;77(8):2240-51. DOI: 10.2527/1999.7782240x
[15] Safieh-Garabedian B, et al. Thymulin related peptide attenuates brain inflammation. Neuropharmacology. 2011;60(6):939-47. DOI: 10.1016/j.neuropharm.2010.11.004
[16] Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-40.
[17] Vickers ER. An Analysis of the Safety and Efficacy of Topical Zinc-Thymulin to treat Androgenetic Alopecia. Hair Ther Transplant. 2017;7:147. DOI: 10.4172/2167-0951.1000147

---

A machinist's indexed reference for the zinc-thymulin record — mechanism assembled part by part from the published literature, no clinic behind the rivets.